January 23, 2023
Biogen Shares Update on FDA Advisory Committee Meeting for Tofersen

On January 23, 2023, the Federal Register  published a notice that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the Peripheral and Central Nervous System Drugs Advisory Committee for the New Drug Application (NDA) for tofersen, an investigational product for the

January 6, 2023
A statement from Biogen on LEQEMBI™ pricing

Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBI TM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety

December 29, 2022
Corporate Statement on Report by the Staffs of the Committee on Oversight and Reform and Committee on Energy and Commerce

Since 2021 Biogen has been working cooperatively with the U.S. House Committee on Oversight and Reform and the U.S. House Energy and Commerce Committee regarding their investigations into the launch of Aduhelm, including providing requested information.

September 26, 2022
Statement: Biogen Statement On Qui Tam Settlement

Biogen has reached a final agreement to pay $900 million to resolve previously disclosed qui tam litigation relating to speaker and consultant programs conducted by the Company prior to 2015. Biogen believes its intent and conduct was at all times lawful and appropriate and Biogen denies all

September 20, 2022

As part of its “Future of Work” initiative to optimize its office footprint in Cambridge to align with reduced space requirements under hybrid work models, today Biogen announced a sale and leaseback agreement with Boston Properties for its building at 125 Broadway and the termination of its lease

August 31, 2022
Statement on Alzheimer’s & Dementia® Journal Publication about Association between Reduction of Amyloid Beta and Slowing of Cognitive and Functional Decline in Alzheimer’s Disease

Today, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association published an updated meta-analysis demonstrating a likely causal association between removal of amyloid beta plaques in the brain and slower cognitive and functional decline in Alzheimer’s disease.

June 15, 2022
Biogen Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner

On behalf of the Biogen community, we want to extend our deepest appreciation to Nancy Leaming and Brian Posner for their years of extraordinary service and dedication as members of our Board of Directors. Ms. Leaming and Mr. Posner, who joined the Biogen Board of Directors in 2008, will retire

April 29, 2022
Biogen Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in US

The US Food and Drug Administration (FDA) has approved an updated full Prescribing Information for ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use, which includes further guidance on how to monitor patients and provides additional safety information.

April 28, 2022
Biogen To Offer Continuity of Care Plan for U.S. Patients Currently Treated with ADUHELM® (aducanumab-avwa)

Biogen is announcing plans to help patients in the U.S. currently on ADUHELM avoid any treatment interruptions following the final national coverage determination by Centers for Medicare & Medicaid Services (CMS) that could result in a loss of coverage for Medicare beneficiaries. All U.S.

April 22, 2022
Update on Regulatory Submission for Aducanumab in the European Union

Biogen Inc. (Nasdaq: BIIB) has notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for aducanumab for the treatment of the early stages of Alzheimer’s disease. The company withdrew its application following interactions with EMA’s